Find Clinical Trials & Studies

Visit the Research & Education Institute

A Phase 2 study of JNJ-90301900 with chemoradiation and durvalumab for non-small cell lung cancer

I'm Interested!

Please call
1-866-373-1464

A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC

Sex: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Cancer - Lung

Study Purpose

The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.

Principal Investigator
Matthew Mirsky MD

Department/Division
Cancer (Any Solid Tumor)

UH IRB: Study20250316
StudyID: JAN1525
ClinicalTrials.gov: NCT06667908

I'm Interested!

Please call
1-866-373-1464

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-866-373-1464